Arbutus Biopharma share price logo

Arbutus Biopharma

NASDAQ: ABUS

Small Cap

$4.21

-0.07

(-1.64%)

as on

Arbutus Biopharma Stock Performance

as on October 31, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $4.14
    $4.29
    downward going graph

    1.66%

    Downside

    1.90%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.50
    $5.45
    downward going graph

    16.86%

    Downside

    29.45%

    Upside

    downward going graph

Arbutus Biopharma share price movements today

Previous Close
$4.28
Open
$4.27
Volume
1.9M
Market Cap
$662.2M
Day's Low - High
$4.14 - $4.29
52 Week Low - High
$3.50 - $5.45

Arbutus Biopharma Historical Returns

1 Month Return
-10.46 %
3 Month Return
-2.95 %
1 Year Return
-11.57 %
3 Year Return
+ 140.45 %
5 Year Return
+ 6.2 %

Arbutus Biopharma Stock Fundamentals & Key Indicators

Check Arbutus Biopharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$662.2M

EPS (TTM)

0.7905

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

5.46

Industry PE ratio

-8.66

PEG Ratio

0.01

EBITDA

153.2M

Revenue (TTM)

181.7M

Profit Margin

99.98%

Return On Equity TTM

90.98%

Arbutus Biopharma vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Arbutus Biopharma with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Arbutus Biopharma image
Arbutus Biopharma
Buy$662.2M6.20%5.4699.98%0.00%
Moderna image
Moderna
Neutral$85.5B-35.47%-26.84-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$134.2B192.00%30.5886.04%0.00%
Regeneron image
Regeneron
Buy$83.7B27.94%19.4284.86%0.45%

Stock Returns calculator for Arbutus Biopharma Stock including INR - Dollar returns

The Arbutus Biopharma stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Arbutus Biopharma investment value today

Current value as on today

₹93,088

Returns

-₹6,912

(-6.91%)

Returns from Arbutus Biopharma Stock

-₹13,017 (-13.02%)

Dollar Impact

₹6,104 (+6.1%)

Analyst Recommendation on Arbutus Biopharma Stock

Based on 11 analysts

BUY

81.82%

Buy

18.18%

Hold

0.00%

Sell

Based on 11 analysts, 81.82% of analysts recommend a 'BUY' rating for Arbutus Biopharma. Average target price of $5.46

Arbutus Biopharma Share Price Target

Get share price movements and forecasts by analysts on Arbutus Biopharma.

What analysts predicted

22.89%UPSIDE

Target Price

$5.46

Current Price

$4.21

Analyzed by

11 Analysts

Target

$5.46

Arbutus Biopharma target price $5.46, a slight upside of 22.89% compared to current price of $4.21. According to 11 analysts rating.

Indian Investors' Interest in Arbutus Biopharma Stock

Search interest for Arbutus Biopharma Stock has decreased by -40% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-40% versus previous 30 day period

Arbutus Biopharma Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
1
1
1
1
1
10
0
1
179
1
Gross Profit
1
1
1
-7
-7
10
0
1
179
1
Operating Income
-19
-21
-21
-13
-34
1
-8
-7
169
-5
EBITDA
-17
-19
-19
-15
-24
2
-7
-3
169
-5
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-17
-19
-19
-12
-24
2
-7
-3
169
-5
Income Tax Expense
-
-
-
-
-
-
-
-
-
-
Net Income
-17
-19
-19
-12
-24
2
-7
-3
169
-5
Net Profit Margin
100.00%
100.00%
100.00%
-459.72%
-407.88%
100.00%
97.92%
98.95%
99.99%
100.00%

Arbutus Biopharma Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
10
5
6
6
10
39
18
6
14
Gross Profit
-52
-52
-51
-40
10
39
18
6
13
Operating Income
-110
-89
-143
-57
-73
-65
-78
-76
-27
EBITDA
-106
-58
-162
-57
-71
-61
-70
-68
-33
Interest Expense
0
0
2
4
2
1
0
0
0
Depreciation
2
2
2
1
1
1
1
1
0
Income Before Tax
-108
-61
-166
-63
-76
-65
-72
-69
-33
Income Tax Expense
-24
-4
-12
-
-
4
-
-
-
Net Income
-84
-57
-153
-63
-76
-69
-72
-69
-33
Net Profit Margin
-485.98%
-881.36%
-858.26%
-586.74%
100.00%
100.00%
100.00%
100.00%
97.42%

Arbutus Biopharma Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-17
-19
-19
-12
-24
2
-7
-3
169
-5
Operating Cash Flow
-19
-14
-20
-10
-13
-15
-5
-4
-8
-6
Investing Cash Flow
11
9
-11
13
11
15
-10
-1
2
-1
Financing Cash Flow
24
24
1
1
2
0
0
1
11
3
Change in Cash
16
19
-30
4
0
0
-15
-4
5
-4

Arbutus Biopharma Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-84
-57
-153
-63
-76
-69
-72
-69
-33
Operating Cash Flow
-48
-67
-71
-51
-67
-35
-85
-64
-39
Investing Cash Flow
27
-4
28
-14
-12
-74
50
22
15
Financing Cash Flow
49
55
37
86
137
31
30
51
5
Change in Cash
30
-17
-5
20
57
-78
-4
10
-18

Global Institutional Holdings in Arbutus Biopharma

Check out the Institutions with significant holdings in Arbutus Biopharma.

Funds
Holdings
Vanguard
4.23%
iShares
4.13%
VANGUARD INDEX FUNDS
3.45%
SPDR
2.06%
Morgan Stanley Insight Fund
1.38%
See all

Arbutus Biopharma News & Key Events

  • img

    Today's Timeline - 12 August

    Wed, 05:00 PM

    -

    Arbutus reports Q2 2026 results: $1.01M revenue, $5.14M net loss, and $178M settlement from Moderna.

Insights on Arbutus Biopharma

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 3 years, ABUS stock has moved up by 132.6%

  • imgNO EFFECT

    Against Peers

    img

    In the last 3 years, Moderna, Inc. Common Stock has given 192.3% return, outperforming this stock by 59.7%

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 720.2% return, outperforming this stock by 729.7%

  • imgNEGATIVE IMPACT

    Revenue Fall

    img

    Revenue is down for the last 2 quarters, 179.12M → 1.01M (in $), with an average decrease of 99.4% per quarter

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 2 quarters, 169.69M → -5.14M (in $), with an average decrease of 103.0% per quarter

About Arbutus Biopharma

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
OrganisationArbutus Biopharma
Headquarters701 Veterans Circle, Warminster, PA, 18974, US
IndustryBiotechnology
CEOLindsay Androski

Key Management of Arbutus Biopharma

Name

Title

Ms. Lindsay Androski J.D., M.B.A.

President, CEO & Chairman

Mr. Tuan Nguyen

Chief Financial Officer

Mr. Andrew J. Sung

General Counsel

Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.

Corporate Secretary

FAQs

What is Arbutus Biopharma share price today?

Arbutus Biopharma share price today is $4.21 as on at the close of the market. Arbutus Biopharma share today touched a day high of $4.29 and a low of $4.14.

What is the 52 week high and 52 week low for Arbutus Biopharma share?

Arbutus Biopharma share touched a 52 week high of $5.45 on and a 52 week low of $3.50 on . Arbutus Biopharma stock price today i.e. is closed at $4.21,which is 22.75% down from its 52 week high and 20.29% up from its 52 week low.

What is Arbutus Biopharma's market capitalisation today?

Arbutus Biopharma market capitalisation is $0.00T as on .

How to invest in Arbutus Biopharma Stock (ABUS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Arbutus Biopharma on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Arbutus Biopharma Stock (ABUS) from India?

Indian investors can start investing in Arbutus Biopharma (ABUS) shares with as little as ₹94.94999694824219 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.50 in Arbutus Biopharma stock (as per the Rupee-Dollar exchange rate as on ). Based on Arbutus Biopharma share’s latest price of $4.21 as on October 31, 2026 at 8:45 am IST, you will get 2.3753 shares of Arbutus Biopharma. Learn more about fractional shares .

What are the returns that Arbutus Biopharma has given to Indian investors in the last 5 years?

Arbutus Biopharma stock has given 6.2% share price returns and 27.22% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?